CME/CE Accredited Session
Sponsored by Industry
Click For Session Details
Session Times Listed in ET
Peter Libby, MD
Lipid risk factors for cardiovascular disease depend in part on lifestyle, but optimum control of lipids often demands additional measures. Low-density lipoprotein (LDL) doubtless contributes causally to atherosclerosis. Recent human genetic findings have substantiated a number of novel targets for lipid-lowering therapy including PCSK9, apolipoprotein C-III, angiopoietin-like protein 3 and 4, apolipoprotein V, and ATP citrate lyase. These discoveries coupled with advances in biotechnology development afford new avenues for management of LDL and other aspects of lipid risk. Beyond LDL, new treatments targeting triglyceride-rich lipoproteins and lipoprotein(a) have entered clinical development. Biological and RNA-directed agents have joined traditional small-molecule approaches, which themselves have undergone considerable refinement. Innovative targeting strategies have increased efficacy of some of these novel interventions and markedly improved their tolerability. Gene-editing approaches have appeared on the horizon of lipid management. Dr. Libby will review this progress into novel biological and therapeutic discoveries, and places them into a practical patient care perspective.
Cardiovascular Specialist, Brigham and Women's Hospital, Mallinckrodt Professor of Medicine, Harvard Medical School, Boston, MA
Ileana L. Piña, MD, MPH
Dr. Piña will compare traditional heart failure treatment targets with current targets, discuss recent clinical trial data, and provide insights into the future of heart failure management.
Clinical Professor of Medicine,, Central Michigan University College of Medicine, Adjunct Professor of Epidemiology and Biostats,, Case Western University
Clinical Insights in NVAF: Reducing the Risk of Stroke and Systemic Embolism
Josh Yamamoto, MD
Patients with nonvalvular atrial fibrillation (NVAF) are at risk of stroke. This lecture will present options for reducing the risk of stroke in patients with NVAF and in patients with NVAF and obesity.
Sponsored by Janssen Pharmaceuticals, Inc.